Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Alcon reports new agents for controlling IOP

Aug. 26, 1997

CAT's anti-TGF-beta2 antibody approved for phase I/IIa trials

Aug. 26, 1997

FDA approves expansion of Sunrise Technologies' hyperopia study

Aug. 26, 1997

InSite Vision initiates phase II study of ISV-120

Aug. 21, 1997

Generic levobunolol approved in Canada

Aug. 13, 1997

FDA releases Staar's implantable contact lens for phase II trials

Aug. 11, 1997

Boston Life Sciences begins preclinical program for ophthalmic indications of antiangiogenic product

July 18, 1997

New insights into glaucoma and implications for drug therapy

July 15, 1997

Prostaglandins in early development at Allergan for glaucoma

July 4, 1997

BioSpecifics Technologies and Bausch & Lomb collaborate on glaucoma studies

June 27, 1997

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...